First Albany Reiterates Buy on ImmunoGen

Analyst David Webber says the new deal with J&J shows potential for the biotech's Tumor-Activated Prodrug technology

First Albany reiterates buy on biotechnology company ImmunoGen (IMGN ).

To continue reading this article you must be a Bloomberg Professional Service Subscriber.